Human Microbiota Transplant (HMT®) therapy is a method of preparing healthy donor stool, and separating the bacteria from it to transplant them into a patient in order to alleviate a variety of gastrointestinal illnesses such as Ulcerative Colitis, Crohn’s Disease, and Irritable Bowel Syndrome (IBS). It is also known as the Fecal Microbiota Transplantation. The therapy is administered via colonoscopy, endoscopy, or enema by qualified and experience medical doctors.
A large number of diverse bacteria and organisms are found in your gastrointestinal tract, which is an important part of your immune system. Gut dysbiosis and the presence of pathogenic microbiota are implicated in the onset and progression of many diseases. The purpose of an HMT® therapy is to restore the probiotic and commensal bacteria and organisms found in a healthy donor’s stool that may be missing or found in low quantities in a patient.
HMT® therapy is often recommended as a treatment for Clostridium difficile (C. diff), a particularly infectious form of chronic diarrhea. It is estimated that over 12,000 HMTs® are performed annually in the U.S. alone for this condition.
HMT® therapy may also be used as a second line treatment for patients who are refractory to antibiotics and traditional pharmaceutical treatments. Patients who struggle with chronic refractory conditions and those facing surgery as a last resort option may benefit from HMT® treatment.
Our medical doctors work with the Hong Kong based Asia Microbiota Bank (AMB) to provide HMT® therapy to IMI clients. The AMB team has a strict donor selection process, a proprietary HMT® production line, and cutting-edge donor sequencing data to ensure safety, the highest quality of HMT® product, and to help to improve clinical outcomes.